- July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") , a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate
These initial results also help identify pre-existing conditions that may affect treatment decisions or require additional monitoring
Barriers That Still Exist Despite encouraging research, several obstacles remain: High monthly cost Limited coverage for weight loss alone Lengthy insurance appeals process Reluctance from employers and insurers to cover newer medications without long-term data Even when semaglutide is approved for coverage, patients often face prior authorization requirements , or their plans may only cover lower doses, certain brands, or specific medical indications
Berberine+ contains a form of berberine (DHB) thats easier for the body to absorb than other forms and is less likely to cause GI discomfort
Diabetes mellitus after solid organ transplantation